| Trial ID: | L6557 |
| Source ID: | NCT01680978
|
| Associated Drug: |
Aleglitazar
|
| Title: |
A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: aleglitazar|DRUG: placebo
|
| Outcome Measures: |
Primary: Cardiac energetics: Change in PCr/ATP ratio using phosphorus magnetic resonance spectroscopy (MRS), from baseline to Week 6 | Secondary: Change in left ventricular diastolic function measured by mitral inflow, tissue Doppler Imaging and magnetic resonance imaging (MRI), from baseline to Week 6|Change in cardiac/hepatic triglyceride content assessed my MRS, from baseline to Week 6
|
| Sponsor/Collaborators: |
Sponsor: Hoffmann-La Roche
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: |Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose:
|
| Start Date: |
2012-10
|
| Completion Date: |
2013-09
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-02
|
| Locations: |
Oxford, OX3 9DU, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01680978
|
